[1] |
Wyatt RJ, Julian BA. IgA nephropathy [J]. N Engl J Med, 2013, 368(25): 2402-2414.
|
[2] |
Tan J, Dong L, Ye D, et al. The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: a network meta-analysis [J]. Sci Rep, 2020, 10(1): 6062.
|
[3] |
Appel GB, Waldman M. The IgA nephropathy treatment dilemma [J]. Kidney Int, 2006, 69(11): 1939-1944.
|
[4] |
Zheng J, Gong X, Wu Z. Immunosuppressive agents in the treatment of IgA nephropathy: a meta-analysis of clinical randomized controlled literature [J]. Niger J Clin Pract, 2020, 23(4): 437-449.
|
[5] |
陈长云,谭丽,唐怡,等. 免疫抑制剂治疗进展期IgA肾病疗效观察 [J]. 四川医学,2019, 40(9): 895-899.
|
[6] |
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient [J]. Kidney Int, 2012, 82(8): 840-856.
|
[7] |
Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy [J]. Am J Kidney Dis, 2015, 66(5): 783-791.
|
[8] |
Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial [J]. Nephrol Dial Transplant, 2005, 20(10): 2139-2145.
|
[9] |
Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy [J]. Kidney Int, 2010, 77(6): 543-549.
|
[10] |
Du B, Jia Y, Zhou W, et al. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis [J]. BMC Nephrol, 2017, 18(1): 245.
|
[11] |
Chen X, Chen P, Cai G, et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy [J]. Zhonghua Yi Xue Za Zhi, 2002, 82(12): 796-801.
|
[12] |
Cheng G, Liu D, Margetts P, et al. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy [J]. Nephrology (Carlton), 2015, 20(2): 77-84.
|
[13] |
Lou T, Wang C, Chen Z, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy [J]. Nephrology (Carlton), 2006, 11(2): 113-116.
|
[14] |
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action [J]. Immunopharmacology, 2000, 47(2-3): 85-118.
|
[15] |
Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF) [J]. Clin Transplant, 1996, 10(1 Pt 2): 77-84.
|
[16] |
Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial [J]. Am J Kidney Dis, 2017, 69(6): 788-795.
|
[17] |
曾艳,周静. 来氟米特在肾脏疾病中的应用进展 [J]. 南昌大学学报(医学版), 2012, 52(2): 85-89.
|
[18] |
Liu Y, Xiao J, Shi X, et al. Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: a meta-analysis [J]. Exp Ther Med, 2016, 11(1): 49-56.
|
[19] |
冯玲,许晓丽,刘琼,等. 来氟米特联合中等剂量泼尼松治疗IgA肾病的临床效果及安全性分析 [J]. 解放军医药杂志,2018, 30(9): 97-100.
|
[20] |
程小丽,杨世峰,师锁江,等. 泼尼松联合来氟米特治疗IgA肾病的近远期疗效观察 [J]. 解放军医药杂志,2020, 32(4): 60-63.
|
[21] |
Liu XW, Li DM, Xu GS, et al. Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome [J]. Int J Clin Pharmacol Ther, 2010, 48(8): 509-513.
|
[22] |
彭健韫,张小如,廖益飞,等. 来氟米特治疗慢性进展性IgA肾病的疗效观察 [J]. 浙江实用医学,2009, 14(2): 107-108, 110.
|
[23] |
陈玉贞,徐家云. 来氟米特联合中小剂量糖皮质激素治疗慢性进展性IgA肾病的疗效及安全性分析 [J/CD]. 中华肾病研究电子杂志,2019, 8(5): 208-212.
|